BR0112734A - Agente terapêutico cristalino - Google Patents

Agente terapêutico cristalino

Info

Publication number
BR0112734A
BR0112734A BR0112734-9A BR0112734A BR0112734A BR 0112734 A BR0112734 A BR 0112734A BR 0112734 A BR0112734 A BR 0112734A BR 0112734 A BR0112734 A BR 0112734A
Authority
BR
Brazil
Prior art keywords
therapeutic agent
crystalline therapeutic
crystalline
pyridylsulfonyl
ethylpiperazine
Prior art date
Application number
BR0112734-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Laurence James Harris
Richard Anthony Storey
Albert Shaw Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BR0112734A publication Critical patent/BR0112734A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
BR0112734-9A 2000-07-28 2001-07-18 Agente terapêutico cristalino BR0112734A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent
PCT/IB2001/001280 WO2002010171A1 (en) 2000-07-28 2001-07-18 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
BR0112734A true BR0112734A (pt) 2004-08-10

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112734-9A BR0112734A (pt) 2000-07-28 2001-07-18 Agente terapêutico cristalino

Country Status (45)

Country Link
EP (1) EP1305314B1 (cg-RX-API-DMAC10.html)
JP (1) JP2004505087A (cg-RX-API-DMAC10.html)
KR (1) KR100457937B1 (cg-RX-API-DMAC10.html)
CN (1) CN1207297C (cg-RX-API-DMAC10.html)
AP (1) AP1400A (cg-RX-API-DMAC10.html)
AR (1) AR032628A1 (cg-RX-API-DMAC10.html)
AT (1) ATE286901T1 (cg-RX-API-DMAC10.html)
AU (2) AU2001272690B2 (cg-RX-API-DMAC10.html)
BG (1) BG107266A (cg-RX-API-DMAC10.html)
BR (1) BR0112734A (cg-RX-API-DMAC10.html)
CA (1) CA2417264C (cg-RX-API-DMAC10.html)
CZ (1) CZ2003126A3 (cg-RX-API-DMAC10.html)
DE (1) DE60108398T2 (cg-RX-API-DMAC10.html)
DO (1) DOP2001000217A (cg-RX-API-DMAC10.html)
DZ (1) DZ3364A1 (cg-RX-API-DMAC10.html)
EA (1) EA004681B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP034454A (cg-RX-API-DMAC10.html)
EE (1) EE200300045A (cg-RX-API-DMAC10.html)
ES (1) ES2231521T3 (cg-RX-API-DMAC10.html)
GE (1) GEP20053494B (cg-RX-API-DMAC10.html)
HR (1) HRP20030061A2 (cg-RX-API-DMAC10.html)
HU (1) HUP0302982A3 (cg-RX-API-DMAC10.html)
IL (1) IL153226A0 (cg-RX-API-DMAC10.html)
IN (1) IN2002MU01649A (cg-RX-API-DMAC10.html)
IS (1) IS6626A (cg-RX-API-DMAC10.html)
MA (1) MA26931A1 (cg-RX-API-DMAC10.html)
MX (1) MX233602B (cg-RX-API-DMAC10.html)
MY (1) MY117831A (cg-RX-API-DMAC10.html)
NO (1) NO324220B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ523226A (cg-RX-API-DMAC10.html)
OA (1) OA12337A (cg-RX-API-DMAC10.html)
PA (1) PA8523501A1 (cg-RX-API-DMAC10.html)
PE (1) PE20020277A1 (cg-RX-API-DMAC10.html)
PH (1) PH12001001922B1 (cg-RX-API-DMAC10.html)
PL (1) PL365133A1 (cg-RX-API-DMAC10.html)
PT (1) PT1305314E (cg-RX-API-DMAC10.html)
SK (1) SK572003A3 (cg-RX-API-DMAC10.html)
SV (1) SV2001000570A (cg-RX-API-DMAC10.html)
TN (1) TNSN01112A1 (cg-RX-API-DMAC10.html)
TW (1) TWI285643B (cg-RX-API-DMAC10.html)
UA (1) UA72631C2 (cg-RX-API-DMAC10.html)
UY (1) UY26854A1 (cg-RX-API-DMAC10.html)
WO (1) WO2002010171A1 (cg-RX-API-DMAC10.html)
YU (1) YU4703A (cg-RX-API-DMAC10.html)
ZA (1) ZA200301457B (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
KR100824193B1 (ko) 2003-04-29 2008-04-21 화이자 인코포레이티드 고혈압 치료에 유용한5,7-디아미노피라졸로[4,3-d]피리미딘
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
JP2007532526A (ja) 2004-04-07 2007-11-15 ファイザー・インク ピラゾロ[4,3−d]ピリミジン類
PT1881985E (pt) 2005-05-12 2011-02-01 Pfizer Formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n- -etil-n-metilamino)-7-(4-metilpiridin-2-il-amino)-1h- -pirazolo[4,3-d]pirimidino-3-carbonil]metanossulfonamida

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2203078T3 (es) * 1998-04-20 2004-04-01 Pfizer Inc. Parazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de la disfuncion sexual.
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
BG107266A (bg) 2003-07-31
MA26931A1 (fr) 2004-12-20
HUP0302982A3 (en) 2005-01-28
DOP2001000217A (es) 2002-10-30
AU2001272690B2 (en) 2005-12-08
PH12001001922B1 (en) 2006-11-21
MXPA03000856A (es) 2003-06-06
SK572003A3 (en) 2004-05-04
AR032628A1 (es) 2003-11-19
EA200300079A1 (ru) 2003-06-26
GEP20053494B (en) 2005-04-25
CZ2003126A3 (cs) 2004-02-18
PT1305314E (pt) 2005-04-29
ECSP034454A (es) 2003-03-10
CA2417264C (en) 2007-06-12
NO324220B1 (no) 2007-09-10
CN1207297C (zh) 2005-06-22
PA8523501A1 (es) 2002-10-24
HUP0302982A2 (hu) 2003-12-29
PL365133A1 (en) 2004-12-27
DE60108398D1 (de) 2005-02-17
AP1400A (en) 2005-04-28
HK1055954A1 (en) 2004-01-30
DZ3364A1 (fr) 2002-02-07
PE20020277A1 (es) 2002-05-11
NO20030416D0 (no) 2003-01-27
YU4703A (sh) 2006-01-16
IL153226A0 (en) 2003-07-06
ATE286901T1 (de) 2005-01-15
IN2002MU01649A (cg-RX-API-DMAC10.html) 2004-12-11
EA004681B1 (ru) 2004-06-24
HRP20030061A2 (en) 2003-04-30
NZ523226A (en) 2003-07-25
UY26854A1 (es) 2002-02-28
DE60108398T2 (de) 2005-12-22
KR100457937B1 (ko) 2004-11-20
JP2004505087A (ja) 2004-02-19
NO20030416L (no) 2003-02-05
OA12337A (en) 2006-05-15
CN1444585A (zh) 2003-09-24
CA2417264A1 (en) 2002-02-07
AU7269001A (en) 2002-02-13
AP2001002234A0 (en) 2001-09-30
TWI285643B (en) 2007-08-21
ZA200301457B (en) 2004-04-28
EP1305314B1 (en) 2005-01-12
UA72631C2 (uk) 2005-03-15
EE200300045A (et) 2004-12-15
WO2002010171A1 (en) 2002-02-07
KR20030016430A (ko) 2003-02-26
SV2001000570A (es) 2002-09-03
MY117831A (en) 2004-08-30
IS6626A (is) 2002-11-18
EP1305314A1 (en) 2003-05-02
MX233602B (es) 2006-01-10
TNSN01112A1 (fr) 2005-11-10
ES2231521T3 (es) 2005-05-16

Similar Documents

Publication Publication Date Title
WO2002053516A3 (fr) Derives de la n(phenylsulfonyl)glycine et leur utilisation en therapeutique
DE60236102D1 (en) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
BR0208338A (pt) Derivados de piridina
SE9704545D0 (sv) Novel compounds
SE9704544D0 (sv) Novel compounds
MY135233A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
MXPA03000510A (es) Sales estables de acido o-acetilsalicilico con aminoacidos basicos.
AU2001282399A1 (en) Resorcinol derivatives
NO954320D0 (no) Lyosfærer omfattende gonadotropin
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
EA200001010A1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
SE9802208D0 (sv) Novel compounds
CY1105028T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
SE9802209D0 (sv) Novel compounds
DOP2001000217A (es) Agente terapéutico cristalino
WO2002057246A3 (en) Inhibitors of cruzipain and other cysteine proteases
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.
ZA983231B (en) Substituted benzyloxyimino compounds.
ATE242763T1 (de) Methoximinophenylessigsäureamide
PY0117546A (es) Agente terapeutico cristalino
BG103779A (en) Crystallohydrate sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidine-3-ilidenmethyl)-1h-i ndole-2-carboxylic acid
BR0212289A (pt) Anticorpos contra caspase-8, preparação e uso do mesmo
GR1004434B (el) Χρησηατουαdiclofenacαhααποδεκτωνααλατωνααυτουαγιαατηνααντιμετωπισηατωναεγκαυματων

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A, 9A E 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011.